secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001193125-22-307898
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara gets EC approval for Ebvallo in EBV+ PTLD; board changes announced
------------------------------------------------------------------------

- EC granted marketing authorization for Ebvallo (tabelecleucel) as monotherapy for relapsed/refractory EBV+ PTLD in adult/pediatric patients 2+ years.
- Approval applies to all 27 EU member states plus Iceland, Norway, and Liechtenstein.
- Directors Ronald C. Renaud and Roy Baynes resigned effective Dec 19, 2022; Carol D. Gallagher appointed Chair.
- Board size reduced from ten to eight directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/d437946d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-307898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer